# Semax vs. Selank: Side-by-Side Comparison — Peptide Peptalk

> A structured comparison of Semax and Selank across peptide class, studied mechanisms, evidence maturity, reported effect profile, and regulatory status. Two distinct cognitive-nootropic research peptides on one table.

Two nootropic heptapeptides with a shared Pro-Gly-Pro tail and very different pharmacology. This page keeps the distinction clear.

## The short version

Semax and Selank are regularly discussed together because they share a structural feature (a Pro-Gly-Pro C-terminal tail) and a common origin (Russian neuropharmacology research, same era). That is where the meaningful overlap ends. Semax is a fragment of the pituitary hormone ACTH; its primary studied endpoints are **neurotrophin upregulation and neuroprotection**. Selank is derived from tuftsin, an immune peptide; its primary studied endpoint is **anxiolytic activity via GABA-receptor modulation**. Grouping them as interchangeable would misrepresent both. The table and commentary below separate the two across the dimensions that matter most for reading the research honestly.

## Side-by-side comparison

| Dimension | Semax | Selank |
|---|---|---|
| **Peptide class** | Synthetic ACTH(4-7) analog; neuropeptide | Synthetic tuftsin analog (TP-7); immunopeptide derivative |
| **Full sequence** | Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| **Primary research endpoint** | Neurotrophin upregulation (BDNF/NGF), neuroprotection, memory | Anxiolytic (anxiety reduction), GABAergic modulation |
| **Primary mechanism** | Region-specific BDNF/NGF gene expression; specific BDNF binding site (KD ~2.4 nM basal forebrain); enkephalinase inhibition | Positive allosteric modulation of GABA receptors; enkephalinase inhibition (weaker, IC50 ~20 µM); Th1/Th2 immune modulation |
| **BDNF link** | Primary finding — strong, region-specific, well-characterized [3][4] | Secondary finding — hippocampal upregulation reported [11] |
| **GABA link** | Not characterized | Primary mechanism — allosteric modulation, gene-expression shifts [8][10] |
| **Main species studied** | Rat, mouse | Rat; some human (Russian clinical) |
| **Human data** | Largely absent in mainstream Western literature; clinical use in Russian stroke/TIA practice | One human immunomodulatory dataset [12]; short-course Russian anxiolytic trials |
| **Evidence maturity** | Moderate preclinical depth; independent Western replication lacking | Moderate preclinical depth; one human dataset; independent replication lacking |
| **Regulatory status** | Rx in Russia/Ukraine (stroke, cognitive impairment); research chemical elsewhere; NOT FDA-approved | Rx in Russia (anxiety/asthenic disorders); research chemical elsewhere; NOT FDA/EMA-approved |
| **WADA status** | Not named; possible S0 catch-all; athletes consult GlobalDRO | Not specifically listed; research framing applies |
| **Community-reported feel** | Fast mental clarity, verbal fluency, task-focus; stimulant-free but fades in hours | Calm-without-sedation, reduced anticipatory anxiety; quieter and more anxiolytic than cognitively energizing |
| **Common downside** | Short duration, irritability at high amounts or with stimulants, non-response | Short duration, over-calm in minority, non-response; nasal irritation |
| **Shared features** | Both: heptapeptide; C-terminal PGP tail; intranasal route; enkephalinase inhibition; Russian origin; research-chemical status outside Russia | |

## How to read this table

The table draws on the same citations that support the individual compound pages on this desk [3][4][7][8][9][10][11][12]. Evidence maturity ratings reflect the published record as of 2025: both peptides have moderate preclinical depth in rodent models, very thin independent Western replication, and no Phase-II or Phase-III trial data in non-Russian populations.

The community-reported effect profiles in the last two rows are **anecdotal, not clinical evidence** — they reflect what nootropic forums, biohacker writeups, and peptide-user communities describe subjectively, clearly labeled as such. They are included because the qualitative difference between the two compounds is real and worth articulating honestly: Semax tends to produce a more energized, focus-forward experience while Selank tends to produce a calmer, anxiety-reducing one — but non-response is common for both, and neither comes with a validated dosing protocol or a long-term safety record outside Russia.

---

Peptide Peptalk is an independent literature digest — every claim is citation-attributed, every anecdote is labeled, and no compound on this desk is for sale.